Structural basis of plaque morphogenesis in alzheimer's disease

Active Grant Awarded

Award ID
R01NS144991
Recipient
Awarding agency
Obligated
$618,967

Award facts

Completion date 4% complete
Place of performance
Wyoming, MI 49503, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke awarded Van Andel Research Institute $618,967 on September 14, 2026, under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The grant, R01NS144991, funds research into the structural basis of amyloid-beta plaque morphogenesis in Alzheimer's disease. The project uses cryo-electron tomography, proteomics, and immunohistochemistry to visualize and characterize amyloid-beta aggregates in their native state in human brain tissue and mouse models, and it correlates distinct pathological stages with the ultrastructural features of plaque types. It also examines the role of midkine, a regulatory growth factor implicated in amyloid-beta aggregation, in disease progression. The first of three specific aims characterizes plaque architecture as Alzheimer's disease progresses, using advanced imaging. The period of performance runs from the award date through June 30, 2031. Performance is recorded at Wyoming, Michigan 49503. The parent program supports extramural NINDS research into the fundamental structure and function of the brain and nervous system, along with research aimed at reducing the burden of neurological disease.

Description

Abstract
Alzheimer's disease (ad) is the most common neurodegenerative disease, characterized by the accumulation of amyloid-beta (AΒ) plaques and TAU tangles, urging for early diagnosis and therapeutic development. AΒ has emerged as a promising biomarker for early detection and a target for immunotherapy strategies aimed at slowing disease progression. Importantly, research indicates that AΒ accumulation occurs before TAU deposition, emphasizing the critical role of early AΒ assembly in the progression of ad. However, our understanding of the native structural characteristics, fibril assembly, and toxicity of AΒ is limited, and significant gaps remain in our knowledge of plaque morphologies and the in vivo process of amyloid assembly, underscoring the need for in situ studies. The primary goal of this project is to elucidate the morphologies and formation processes of AΒ aggregates in ad using advanced structural and biochemical techniques. By employing a combination of CRYO-electron tomography (CRYO-ET), proteomics, and immunohistochemistry, we aim to visualize and characterize AΒ aggregates in their native state in both human brain tissue and mouse models. This multifaceted approach will enable US to correlate distinct pathological stages with the ultrastructural features of various AΒ plaque types, thereby enhancing our understanding of how different AΒ filament morphologies contribute to ad pathology. Additionally, we will investigate the role of midkine, a regulatory growth factor implicated in AΒ aggregation, to clarify its contribution to disease progression. To achieve these goals, we will pursue three specific aims: first, we will characterize the architecture of distinct AΒ plaques as ad progresses using advanced imaging techniques to reveal the structural and compositional properties of AΒ plaques, offering insights into their role in ad pathogenesis. Second, we will explore the morphology changes of AΒ plaque formation that are associated with development of neuropathology across different time points in genetic models of ad. Lastly, we will investigate the role of midkine in AΒ aggregation and its impact on the properties of type I and II AΒ fibrils. We aim to illuminate the stages of AΒ aggregation and assess the influence of factors like midkine on aggregate formation, which could lead to the identification of new therapeutic targets. Through these aims, this research seeks to advance our understanding of AΒ plaque dynamics, ultimately contributing to improved diagnostic strategies and therapeutic approaches for alzheimer's disease.

Quick answers

Who received award R01NS144991?

R01NS144991 was awarded to Van Andel Research Institute by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 14, 2026.

How much is award R01NS144991 worth?

$618,967 has been obligated on R01NS144991.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award